Characterization of tau oligomeric seeds in progressive supranuclear palsy. - Wikidata - wikimedia - TriplyDB

Characterization of tau oligomeric seeds in progressive supranuclear palsy.

Characterization of tau oligomeric seeds in progressive supranuclear palsy.

http://www.wikidata.org/entity/Q34500234

about

Neuronal network disintegration: common pathways linking neurodegenerative diseases Tau Oligomers: The Toxic Player at Synapses in Alzheimer's Disease Key emerging issues in progressive supranuclear palsy and corticobasal degeneration Co-expression of truncated and full-length tau induces severe neurotoxicity Propagation of tau pathology: hypotheses, discoveries, and yet unresolved questions from experimental and human brain studies.Roles of tau protein in health and disease.Phosphoregulation of Tau modulates inhibition of kinesin-1 motility.Cerebral Microvascular Accumulation of Tau Oligomers in Alzheimer's Disease and Related Tauopathies.Tau oligomers in cerebrospinal fluid in Alzheimer's disease.Tau Oligomers: Cytotoxicity, Propagation, and Mitochondrial Damage.Invited review: Drug development for tauopathies.The interrelationship of proteasome impairment and oligomeric intermediates in neurodegeneration.Therapeutic Strategies for Restoring Tau Homeostasis.Signaling pathways and posttranslational modifications of tau in Alzheimer's disease: the humanization of yeast cells.Tau Oligomers Associate with Inflammation in the Brain and Retina of Tauopathy Mice and in Neurodegenerative Diseases.Tau Oligomers as Pathogenic Seeds: Preparation and Propagation In Vitro and In Vivo.Tau-mediated Neurodegeneration and Potential Implications in Diagnosis and Treatment of Alzheimer's Disease.Production of recombinant tau oligomers in vitro.Clinical heterogeneity in progressive supranuclear palsy: challenges to diagnosis, pathogenesis and future therapies.Tau Oligomers Derived from Traumatic Brain Injury Cause Cognitive Impairment and Accelerate Onset of Pathology in Htau Mice.Prospects for strain-specific immunotherapy in Alzheimer's disease and tauopathies.Tau Spreading Mechanisms; Implications for Dysfunctional Tauopathies.Is it Useful to Classify PSP and CBD as Different Disorders? Yes

P2860

Q26750287-778270BC-E1DC-4848-88D3-51916593C68D Q26773154-61D82F81-77F2-43A7-9C69-069BB502D48C Q28084976-8F50D365-06FE-49F3-8E84-F967ADDBE9B5 Q30829185-13000B0C-9DC7-4289-8DAE-D544FF925F80 Q31024674-055E9D1B-3871-4EED-A6BB-D2F07AE103ED Q33559303-691F089D-9552-4E14-9206-5B6B33DDAD75 Q33563366-B2679070-83C2-442A-A05B-D760ABF92014 Q33714234-2C172FE6-41AB-4BCE-846A-1D4EC372ABCB Q37733987-746011E7-066F-4BBB-90C9-66BC18A43A58 Q37736091-67619DF5-4931-4CED-83D9-FFD605E4BF36 Q38263698-0142CCA6-F436-4C71-853E-D63D43FBF614 Q38520167-76A2EDA8-5C02-4AFA-B987-5A2CD7842011 Q39118898-A5046283-5D0E-456F-8928-39E48CBE6986 Q39208164-37E92BC5-0696-4712-977C-B13D46C35013 Q42355513-7C3FF5B8-73CA-400D-BEE5-49167EA1C93F Q46445872-0F8E2C04-434E-45A7-80CC-7AD9EDA0E830 Q47296152-CCA24754-9950-4FD3-978A-60EAA31EA2F1 Q47839739-F05EC1BE-BFAA-45B1-8A4F-9FE0A21F6798 Q48717188-A36FADB4-301E-451E-8D34-EB3B93B50661 Q49052601-916C5D8C-8316-4B5A-AB64-B78AE4317423 Q50532471-B5316D23-148D-48DC-A358-16A914463C70 Q52679169-FE63FA12-8631-405F-9486-B9BF23559C0A Q58575653-AB379269-8B48-4DFE-B0B3-65D53668B3F4

P2860

Characterization of tau oligomeric seeds in progressive supranuclear palsy.

http://www.wikidata.org/entity/Q34500234

description

2014 nî lūn-bûn

@nan

2014 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Characterization of tau oligomeric seeds in progressive supranuclear palsy.

@ast

Characterization of tau oligomeric seeds in progressive supranuclear palsy.

@en

Characterization of tau oligomeric seeds in progressive supranuclear palsy.

@nl

type

label

Characterization of tau oligomeric seeds in progressive supranuclear palsy.

@ast

Characterization of tau oligomeric seeds in progressive supranuclear palsy.

@en

Characterization of tau oligomeric seeds in progressive supranuclear palsy.

@nl

prefLabel

Characterization of tau oligomeric seeds in progressive supranuclear palsy.

@ast

Characterization of tau oligomeric seeds in progressive supranuclear palsy.

@en

Characterization of tau oligomeric seeds in progressive supranuclear palsy.

@nl

P1433

Q34500234-465C236A-5DD8-4788-8B75-5975D26D3E9A

P1476

Q34500234-A8F9E556-7B82-450F-ACF3-555DA38432AD

P2093

Q34500234-115F767D-328A-4AA5-A58D-BD79652CA5E6

Q34500234-1FB29C62-3B89-4005-975B-E368CDB02F56

Q34500234-480A4669-EE0E-4418-BAD3-F4599FFEBBB9

Q34500234-61C55FD0-2F4B-42D3-83BB-70549292C58C

Q34500234-75AE0F53-4301-4364-A80F-89163916DAE2

Q34500234-C592CA3F-814C-47A7-B2D1-6F0D3651B36C

P2860

Q34500234-04E5A2E2-FCD2-4FC0-A244-A11C26538A0D

Q34500234-16161EB5-1862-442F-8EF3-B007E0A32FF7

Q34500234-18EB64C9-39ED-4157-BF86-F956276F1643

Q34500234-27A7A3A5-5BC6-4071-90F5-46219823701F

Q34500234-2A995355-B1EF-495D-97EA-E63DD40BA279

Q34500234-2D786354-3D93-4CAF-9B7F-45F69A513E9B

Q34500234-380F29E2-631F-47AF-9582-CA796BB1E9B2

Q34500234-3C3DB183-6A5F-49E3-9763-742FDEADCFA8

Q34500234-3C88858B-569D-406F-BC20-94FDFA2C261F

Q34500234-3C899B7C-D70A-430C-B6EA-5FD3800D7008

P2888

Q34500234-D5BB2532-2C27-4710-A930-5A00C13798CC

P304

Q34500234-362DAA4E-5BBC-475B-9EFA-ADA17218612D

P31

Q34500234-D006BE2D-4B6E-4BDC-802F-E52132B1BC01

P356

Q34500234-955A7E90-15B5-4AD4-8833-30D08C676AE9

P478

Q34500234-89958050-3D01-4B84-B22C-891FB99BC200

P577

Q34500234-D858BF4D-7980-474A-AD99-D3208EC5FAC8

P5875

Q34500234-9EE84448-8716-4084-8CAA-87944DA3A7E9

P6179

Q34500234-5A39A20E-AB02-46F1-9B69-4DF0B7661E0E

P698

Q34500234-904F53A6-6016-49BD-A128-7774ACDD9119

P932

Q34500234-E2020EEE-D5FC-4A63-9DEA-E8ADEAF1C2A7

P356

P1433

Acta neuropathologica communications

P1476

Characterization of tau oligomeric seeds in progressive supranuclear palsy.

@en

P2093

Cristian A Lasagna-Reeves

http://www.w3.org/2001/XMLSchema#string

Juan Troncoso

http://www.w3.org/2001/XMLSchema#string

Julia E Gerson

http://www.w3.org/2001/XMLSchema#string

Marcos J Guerrero-Muñoz

http://www.w3.org/2001/XMLSchema#string

Rakez Kayed

http://www.w3.org/2001/XMLSchema#string

Urmi Sengupta

http://www.w3.org/2001/XMLSchema#string

P2860

Inhibitory role for dual specificity phosphatase VHR in T cell antigen receptor and CD28-induced Erk and Jnk activation

Hyperphosphorylation induces self-assembly of tau into tangles of paired helical filaments/straight filaments

Synapse loss and microglial activation precede tangles in a P301S tauopathy mouse model

Tau accumulation causes mitochondrial distribution deficits in neurons in a mouse model of tauopathy and in human Alzheimer's disease brain

Intracellular processing of aggregated tau differs between corticobasal degeneration and progressive supranuclear palsy.

Multiple isoforms of human microtubule-associated protein tau: sequences and localization in neurofibrillary tangles of Alzheimer's disease

Tau suppression in a neurodegenerative mouse model improves memory function

Age-dependent impairment of cognitive and synaptic function in the htau mouse model of tau pathology

Identification of oligomers at early stages of tau aggregation in Alzheimer's disease.

Do neuronal inclusions kill the cell?

P2888

P304

73

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/2051-5960-2-73

http://www.w3.org/2001/XMLSchema#string

P478

2

http://www.w3.org/2001/XMLSchema#string

P577

2014-06-14T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

263097052

http://www.w3.org/2001/XMLSchema#string

P6179

1042244987

http://www.w3.org/2001/XMLSchema#string

P698

24927818

http://www.w3.org/2001/XMLSchema#string

P932

4229782

http://www.w3.org/2001/XMLSchema#string